 beta(3)-adrenoceptor agonist, (RR+SS)-(+/-)-4-[2-)2-)3-chlorophenyl)-2-hydroxyethyl)amino)propyl]ph enoxyacetate (BRL37344), stimulated fuel utilisation isolated mouse soleus muscle concentrations 10- 100-fold lower required stimulate lipolysis brown adipocytes. 1x10(-10) BRL37344, uptake phosphorylation 2-deoxyglucose increased (40%), glucose-oxidation (50%), palmitate-oxidation (70%) oxidation [2-14C]pyruvate (2-fold), indicating stimulation tricarboxylic acid cycle reactions. Oxidation [1-14C]pyruvate unaffected, indicating stimulation pyruvate dehydrogenase activity. beta(3)-adrenoceptor agonists, disodium(RR)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]- 1,3-benzodioxazole-2,2-dicarboxylate (CL316,243, 1x10(-7) M) (S)-4- inverted question mark2-[2-hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl inverted question markpheno xymeth ylcyclohexylphosphiric acid lithium salt (SB226552, 1x10(-9) M), achieved similar stimulation 2-deoxyglucose uptake phosphorylation (+/-)-4-(3-t-butylamino-2-hydroxypropoxy)benzimidazol-2-one (CGP12177A) effect. inhibitor protein kinase A, H-89 (isoquinolinesulfonamide), little effect stimulation pyruvate-oxidation BRL37344, specific inhibitor protein kinase C, bisindolylmaleimide IX, reduced stimulated rate slightly basal values. consider responses provide evidence presence novel beta-adrenoceptor skeletal muscle, termed beta(skel)-adrenoceptor.